NCT06889948View on ClinicalTrials.gov

The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Kidney FailureParaproteinemiasGlomerulonephritis
Interventions
DRUG

Daratumumab

All patients will receive either fixed-dose daratumumab as a single agent therapy or fixed-dose daratumumab combined with stem cell transplantation.

Trial Locations (1)

Unknown

RECRUITING

Helsinki University Hospital, Helsinki

All Listed Sponsors
collaborator

Janssen, L.P. - Investigator Initiated Studies Program

UNKNOWN

lead

Helsinki University Central Hospital

OTHER